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Abstract
Background Treatment options in patients with amyloi-
dotic transthyretin (ATTR) cardiomyopathy are limited.
Epigallocatechin-3-gallate (EGCG), the most abundant
catechin in green tea (GT), inhibits fibril formation from
several amyloidogenic proteins in vitro. Thus, it might also
halt progression of TTR amyloidosis. This is a single-
center observational report on the effects of GT con-
sumption in patients with ATTR cardiomopathy.
Methods 19 patients with ATTR cardiomyopathy were
evaluated by standard blood tests, echocardiography, and
cardiac MRI (n = 9) before and after consumption of GT
and/or green tea extracts (GTE) for 12 months.
Results Five patients were not followed up for reasons of
death (n = 2), discontinuation of GT/GTE consumption
(n = 2), and heart transplantation (n = 1). After
12 months no increase of left ventricular (LV) wall thick-
ness and LV myocardial mass was observed by echocar-
diography. In the subgroup of patients evaluated by cardiac
MRI a mean decrease of LV myocardial mass (-12.5 %)
was detected in all patients. This was accompanied by
an increase of mean mitral annular systolic velocity of
9 % in all 14 patients. Total cholesterol (191.9 ± 8.9 vs.
172.7 ± 9.4 mg/dL; p \ 0.01) and LDL cholesterol
(105.8 ± 7.6 vs. 89.5 ± 8.0 mg/dL; p \ 0.01) decreased
significantly during the observational period. No serious
adverse effects were reported by any of the participants.
Conclusions Our observation suggests an inhibitory
effect of GT and/or GTE on the progression of cardiac
amyloidosis. We propose a randomized placebo-controlled
investigation to confirm our observation.
K. Altland, H. A. Katus contributed equally to this work.
Electronic supplementary material The online version of this
article (doi:10.1007/s00392-012-0463-z) contains supplementary
material, which is available to authorized users.
A. V. Kristen (&)  S. Lehrke  S. Buss  D. Mereles 
H. Steen  P. Ehlermann  S. Hardt  E. Giannitsis 
T. J. Dengler  H. A. Katus
Department of Cardiology, Angiology, and Respiratory
Medicine, University Hospital Heidelberg, Im Neuenheimer
Feld 410, 69120 Heidelberg, Germany
e-mail: Arnt_Kristen@med.uni-heidelberg.de
R. Schreiner
Laboratory of Dr. Limbach and Associates,
Im Breitspiel 15, 69126 Heidelberg, Germany
U. Haberkorn
Department of Nuclear Medicine, University of Heidelberg,
Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
P. A. Schnabel
Institute of Pathology, Heidelberg University, Im Neuenheimer
Feld 220/221, 69120 Heidelberg, Germany
R. P. Linke
Reference Center of Amyloid Diseases, amYmed,
Am Klopferspitz 19, 82152 Martinsried, Germany
C. Ro¨cken
Institute of Pathology, Christian-Albrechts-University,
Arnold-Heller-Straße 3/14, 24105 Kiel, Germany
E. E. Wanker
Max Delbru¨ck Center for Molecular Medicine,
AG Neuroproteomics, 13092 Berlin, Germany
K. Altland
Institute of Human Genetics, Giessen University,
Schlangenzahl 14, 35392 Giessen, Germany
123
Clin Res Cardiol (2012) 101:805–813
DOI 10.1007/s00392-012-0463-z
Keywords Cardiomyopathy Green tea
Transthyretin-derived amyloidosis
Epigallocatechin-3-gallate
Introduction
Cardiac ATTR amyloidosis is observed as the predominant
manifestation associated with distinct mutations in the TTR
gene also known as familial amyloid cardiomyopathy (FAC)
[1] and represents the major complication in patients of
advanced age with familial amyloid polyneuropathy (FAP)
[2]. Wild-type TTR (senile systemic amyloidosis, SSA) has
been found in 25 % of post-mortem cardiac biopsies from
patients older than 85 years [3]. Pre-mortem diagnosis is
rare, but prevalence appears to be underestimated. By routine
scintigraphic skeletal imaging SSA has been detected in 2
males among 374 consecutive admissions older than
60 years, indicating a prevalence of about 0.5 % [4].
Without treatment both hereditary and non-hereditary
forms of cardiac ATTR amyloidosis are progressing and
fatal after several years. Patient’s prognosis mostly
depends on the extent of cardiac involvement. Despite that
therapeutic options for patients with light-chain amyloi-
dosis have been ameliorated during the past years [5],
treatment concepts for patients with advanced cardiac
involvement in TTR amyloidosis are still limited. Liver
transplantation has become an accepted causative treatment
to stop the hepatic production of variant TTR [6] in FAP
and FAC patients, but progression of cardiac amyloid
deposition has been observed rather frequently after liver
transplantation [7]. Patients with advanced cardiac amy-
loidosis are deemed ineligible for this approach due to high
treatment-related mortality. Liver transplant has no thera-
peutic effect in SSA patients. Heart transplantation remains
the only therapeutic option for advanced cardiac TTR
amyloidosis but is limited to patients at age \65 years.
Assuming a prevalence of 0.5 % for clinically relevant
cardiac ATTR amyloidosis in the growing elderly population
([60 years) there is a high need for novel effective preventive
and therapeutic measures against this otherwise fatal disease.
Experimental studies evaluated the suppression of hepatic
synthesis of TTR by antisense oligonucleotids [8]. Several
small compounds, e.g. non-steroidal anti-inflammatory drugs
or derivatives [9], flavonoids [10], xanthones of plant origin
[11], and sulfite [12] have been suggested for treatment of
ATTR amyloidosis by inhibiting TTR tetramer dissociation
and/or impairing amyloid fibril formation. Recently,
Tafamidis (Fx-1006A), a strong inhibitor of TTR tetramer dis-
sociation has been approved for the treatment of patients with
FAP stage I (http://www.ema.europa.eu/ema/index.jsp?curl=
pages/medicines/human/medicines/002294/human_med_0
01498.jsp&mid=WC0b01ac058001d124).
Laboratory studies have shown that human TTR is
rather stable at physiological pH 7.4 but tends to denature
at pH 6.5–7, levels observed under inflammatory or
ischemic conditions, indicating that prevention of such
conditions could help to reduce the risk for TTR to
denature and become converted into amyloid [13]. Recent
in vitro experiments have shown that 50 lM epigalloca-
techin-3-gallate (EGCG), the most abundant catechin in
green tea (GT), efficiently inhibits fibril formation from
amyloid ß-protein, a-synucleine [14], and TTR [15] and
converts existing fibrils into non-fibril conformers [16]. In
a FAP transgenic mouse model a reduction of amyloid
deposition was observed after treatment with 100 mg
EGCG per kg body weight per day over a period of
6 weeks [17]. A retired member of our faculty (Dr.
W. Hunstein), observed a 25 % decrease of the LV wall
thickness after having consumed 1.5–2 L of GT daily over
11 months [18, 19]. According to manufacturer informa-
tion the green tea used by Hunstein contained about
350 mg EGCG per liter when brewed for 5 min at
100 C. A decrease of LV wall thickness [2 mm was
observed in 11 AL amyloidosis patients with history of
regular GT consumption [20]. The initial in vitro studies
by Ehrnhoefer et al. [14] as well as the personal in vivo
observation of Hunstein [18] stimulated our trial to
reproduce Hunstein’s observation in patients with cardiac
ATTR amyloidosis.
Methods
The present cohort at the Heidelberg Amyloidosis Center
consisted of 19 patients (15 males, 4 females; mean age
66.3 ± 2.0 years) with hereditary (n = 10, 53 %) or non-
hereditary SSA (n = 9, 47 %) cardiac ATTR amyloidosis
and compensated heart failure. Patients were observed over
a period of 12 months while consuming GT and/or GTE.
Routine medication was continued during this period. The
observation was approved by the institutional Ethics
Committee of the University of Heidelberg and complied
with the Declaration of Helsinki [21].
All patients had biopsy-proven ATTR confirmed by
green birefringence of Congo red-stained sections viewed
in polarized light and subsequent immunohistochemical
classification of the amyloid deposits [22, 23]. They were
screened for amyloidogenic TTR variants by isoelectric
focusing of plasma TTR and by sequencing of genomic
DNA [24]. Clonal light-chains were examined by serum/
urine immunofixation electrophoresis and a serum-free
light-chain test. Monoclonality was excluded in all
patients. All patients had increased tracer retention in the
heart by 99mTc DPD scintigraphy (Fig. 1) indicating car-
diac ATTR depositions [25, 26].
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In addition to cardiac involvement patients with hered-
itary TTR amyloidosis had clinical evidence for involve-
ment of gut (n = 4; 40 %), and/or peripheral nerves
(n = 8; 80 %). The main clinical symptoms at study entry
were polyneuropathy in six patients and exertional dyspoea
in eight patients. Mean functional heart failure class
according to New York Heart Association was 2.0 ± 0.2.
Four patients (40 %) with hereditary amyloidosis had
orthotopic liver transplantation prior to study inclusion.
After having received written informed consent for
participation in this observational project the patients were
evaluated by standard blood tests, echocardiography with
Doppler studies, and cardiac magnetic resonance imaging
(cMRI). Follow-up controls were performed by clinical
investigation at the Heidelberg Amyloidosis Center 6 and
12 months after study inclusion.
Echo- and electrocardiography
All transthoracic echocardiograms were performed accord-
ing to a routine protocol using commercially available
ultrasound diagnostic systems (Vivid 7, GE Healthcare,
Milwaukee, WI, USA) by experienced investigators. Three
cardiac cycles were stored in cine loop format for offline
analysis. In patients who were in atrial fibrillation five con-
secutive beats were averaged. Offline analysis of echocardi-
ography examinations of both cohorts were conducted on a
commercially available workstation (Centricity Cardiology
CA1000 2.0, GE Medical Systems, Milwaukee, WI, USA)
independently by three expert investigators blinded by time
point. M-mode or 2D recordings were analyzed for diastolic
interventricular septum thickness (IVS), diastolic posterior
wall thickness, end-diastolic and end-systolic left ventricular
(LV) cavity diameter, LV systolic and longitudinal function,
and pericardial effusion [27]. Left ventricular mass was cal-
culated by the Devereux formula [28]. LV function was
assessed according to standard definitions [29] and was
considered markedly impaired at \40 % by the biplane
Simpson method (2D/4D). LV longitudinal function was
assessed by mitral and tricuspid annular plane systolic
excursion from the apical 4-chamber view by measuring the
maximum excursion of the lateral site of the annulus after
ventricular systole by M-mode imaging. Pulsed-wave
Doppler tissue imaging of the mitral annulus was done using a
standard spectral Doppler sample volume gate length of
0.17 cm. The sample volume was placed on the lateral mitral
annulus in the apical four-chamber view to measure systolic
velocity.
Cardiac magnetic resonance imaging
CMRI was performed on a 1.5-T whole body MRI scanner
(Achieva Intera1 Philips Medical Systems, Best, The Neth-
erlands) equipped with a five-element cardiac receiver coil
according to a protocol that has been described in detail
previously [30]. Resting LV function was determined by cine
images using a segmented k-space balanced fast-field-echo
sequence (Steady-State-Free-Precession, matrix = 160/256,
sense-factor = 2, flip angle = 60, slice thickness/gap =
8/2 mm) in contiguous short axes covering the whole left
ventricle from base to apex as well as two, three, and chamber
views in anatomically correct heart axes. Data analysis was
carried out on a commercially available cMRI workstation
(Philips Viewforum, Version 3.4, Best, The Netherlands) by
three independent observers blinded by time point. LV end-
diastolic and endsystolic volumes with resulting ejection
fraction as well as myocardial mass in diastole were deter-
mined from short axes by manual delineation of endocardial
and epicardial borders excluding papillary muscles.
Dosage of green tea and green tea extract
The protocol followed that of Hunstein [18]. All patients were
asked for a daily intake of approximately 500–700 mg
Fig. 1 Whole body scintigraphy for visualization of cardiac trans-
thyretin amyloid Cardiac tracer uptake obtained 3 h after application
of 736 MBq technetium-99 m 3,3-diphosphono-1,2-propanodi-
carboxylic acid (99mTc-DPD) indicating cardiac ATTR amyloid
deposition
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EGCG either by drinking 1.5–2 L of GT per day (10 g/L
Green Darjeeling, FTGFOP1, Teekampagne Projekt-
werkstatt GmbH, Berlin, Germany; brewed 3–5 min at
100 C, and containing about 340 mg EGCG/L; [31]) or by
the intake of caffeine-free GTE capsules (praevent-loges,
Dr. Loges ? Co. GmbH, Winsen/Luhe, Germany, contain-
ing 300 mg GTE with 75 mg EGCG/capsule). Patients were
asked to document in a protocol their daily GT and/or GTE
consumption as well as any adverse effects. This protocol
was used to calculate the mean daily EGCG intake during
the observational period [(total GT (in L) 9340 mg/L 9
total number of GTE capsules 975 mg)/days of observa-
tion].
Quantification of plasma EGCG levels
Blood samples were collected in EDTA-containing tubes.
As EGCG rapidly changes its structure above pH 7, binds
to proteins, and becomes oxidized, the blood samples
were immediately transferred to an ice bath and the
plasma was separated from the cellular fraction by cen-
trifugation at 4 C. One ml of each plasma sample was
mixed with 50 lL of an ascorbate-EDTA solution [0.4 M
NaH2PO4 buffer containing 20 % ascorbic acid and
0.1 % EDTA (pH 3.6)] and stored at -20 C until
analysis. The EGCG levels were measured via LC-
MSMS (liquid chromatography equipped with a triple
quadruple mass spectrometer). In short, 100 lL of the
stabilized plasma was acidified with 20 lL 5 N HCl and
extracted twice with ethyl acetate. The organic phase was
evaporated and resolved in 300 lL of a solution con-
taining two volumes of a 20-mM ammonium acetate
buffer pH 3.6 and 1 volume methanol. The separation
was performed on a C18 Reversed-Phase Column with a
gradient of 20 mM ammonium acetate against methanol.
The transitions monitored in the mass selective detector
under negative modus were 457 (precursor Ion) to 125
product Ion, 457 (precursor Ion) to 169 product Ion
(qualifier), and as internal standard 319 (precursor Ion) to
191 product Ion.
Statistical analysis
Continuous data were expressed as median and range.
Categorical variables were expressed as absolute num-
bers and percentages. Differences between the non-
parametric, continuous parameters assessed at study
inclusion and at 12-month follow-up visit were compared
by the Wilcoxon rank-sum test. p \ 0.05 was considered
statistically significant. Statistical analyses were per-
formed using StatView (Version 5.0, SAS Institute, Cary,
NC, USA).
Results
Patients
Of a total of 19 examined patients five patients were lost
during the study period either due to death (n = 2), dis-
continuation of green tea consumption (n = 2), or heart
transplantation (n = 1). All study patients (n = 14) were
assessed by echocardiography. One patient died 1 month
after study inclusion due to cardiac failure; the second
death occurred after a 5-month stay at the intensive care
unit with prolonged artificial ventilation, hemofiltration,
recurrent infections, and finally death due to multi-organ
failure after drainage of a retroperitoneal hematoma. Due
to prior placement of cardiac pacemaker (n = 2), internal
defibrillator (n = 1), orthopedic prosthesis (n = 1), or
claustrophobia (n = 1) cMRI images were obtained only
from 9 of the 14 study patients. The clinical state of the 14
study patients as well as oral heart failure medication
remained unchanged during the observation period. None
of the patients was hospitalized due to cardiac decompen-
sation. The main clinical demographics of the 14 patients
with 12-month follow-up are shown in Table 1. Detailed
data for all 14 patients at the beginning and the end of the
observation period are given in Table 1S (Supplemental
information).
Quantification of plasma EGCG levels, cholesterol,
and NT-proBNP
All patients documented their daily intake of GT/GTE.
According to the protocols mean oral EGCG intake was
calculated as 547 ± 49 mg per day. Individual mean daily
EGCG intake is shown in the supplementary table. No
serious adverse effects were reported. Mean EGCG plasma
level after 12 h of GT/GTE abstinence was 48 ± 14 lg/L
(0.1 ± 0.03 lM). Mean plasma EGCG level 2 h after
intake of 150 mg EGCG as GTE (2 capsules) was
253 ± 68 lg/L (0.55 ± 0.15 lM, range 0.1–1.8 lM).
During the observation period mean total cholesterol and
LDL cholesterol decreased from 191.9 ± 8.9 to 172.7 ±
9.4 mg/dL (p \ 0.01) and from 105.8 ± 7.6 to 89.5 ±
8.0 mg/dL (p \ 0.01), respectively (see Fig. 2a, b). Mean
HDL cholesterol remained unchanged (58.9 ± 3.9 to
55.4 ± 4.6 mg/dL (p \ 0.01).
Echocardiography analysis
During 12 months of GT/GTE intake a statistically sig-
nificant decrease by 6.5 % of the thickness of IVS was
observed (Fig. 3a). Thickness of IVS decreased in 12/14
patients (86 %); in 4 patients by C2 mm, remained
unchanged in 1 patient (7 %) and increased 2 mm in 1
808 Clin Res Cardiol (2012) 101:805–813
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patient (7 %). Mean thickness of the posterior wall did not
change during the study period (Fig. 3b). A decrease of the
posterior wall thickness was observed in 10/14 patients
(71 %; C2 mm in 2 patients), and an increase of less than
2 mm was detected in 4/14 patients (29 %). Mean LV
myocardial mass did not increase during the observational
period of GT/GTE intake (Fig. 3c). In detail, LV myo-
cardial mass decreased in 9/14 (64 %) patients, increased
in 3/14 (21 %) patients, and remained unchanged in 2/14
(14 %) patients. A significant improvement of the mean
systolic velocity of the lateral mitral annulus was observed
(improved in 10/14 patients (71 %); diminished in 4/14
(14 %) patients; Fig. 3d). More detailed echocardiographic
data are shown in Table 1S (Supplemental information).
Inter-observer variability of echocardiography was 7.6 %.
cMRI analysis
Clinical characteristics of the subgroups of patients asses-
sed by cMRI (n = 9) did not differ from the whole patient
cohort (Table 1). We observed a significant average
Table 1 Clinical demographics
of the patients included in the
study
FU follow-up
a Body weight (kg)/body height
(m2) 9 plasma albumin (d/L)
Clinical demographics All patients (n = 14) Patients studied by cMRI (n = 9)
Mean ± SEM or number (%) Mean ± SEM or number (%)
Age (years) 66 ± 3 68 ± 2
Gender male/female 10 (71 %)/4 (29 %) 7 (78 %)/2 (22 %)
Height (cm) 169 ± 2 171 ± 2
Weight (kg) 71 ± 3 72 ± 3
Modified body mass indexa 1,080 ± 46 1,084 ± 45
Patients with variant TTR 8 (57 %) 5 (56 %)
Val20Ile 0 0
Val30Met 5 (36 %) 4 (44 %)
Gly47Glu 1 (7 %) 0
Gly47Ala 1 (7 %) 0
Ile107Val 1 (7 %) 1 (12 %)
Patients with SSA 6 (43 %) 4 (44 %)
Orthotopic liver transplant 2 1
Pacemaker placement 2 –
Defibrillator placement 1 –
Orthopedic prosthesis 1 –
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Fig. 2 Changes of lipid profile during the study period Total
cholesterol (a) and LDL cholesterol (b) plasma levels of patients
with TTR amyloidosis before (t0) and after 12 months (t12) of green
tea consumption
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Fig. 3 Echocardiographic changes during the study period (a) Inter-
ventricular septum thickness, (b) posterior wall thickness, (c) left
ventricular myocardial mass, and (d) systolic velocity of the lateral
mitral annulus (MASV) assessed by echocardiography in patients
with TTR amyloidosis before (t0) and after 12 months (t12) of green
tea consumption
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decline of LV myocardial mass by 12.5 % (Fig. 4). In none
of the patients an increase of LV myocardial mass was
observed. LV ejection fraction remained unchanged
(56.7 ± 4.7 vs. 57.2 ± 3.7 %; ns). Detailed cMRI findings
are shown in Table 1S (Supplemental information). Inter-
observer variability of MRI was 4.2 %.
Discussion
This is the first single center observation of myocardial
parameters during daily consumption of EGCG as GT or
GTE for 1 year in patients with cardiac ATTR amyloidosis.
No progression of cardiac wall thickness and mass as
indicators of ATTR amyloid deposition was observed in
these patients during the 1-year observation period. No
serious adverse effects were reported.
EGCG as the most abundant catechin in GT has been
claimed to prevent all-cause cardiovascular morbidity and
mortality [32]. These effects might in part be caused by its
lipid lowering effects [33] as observed in all patients of the
present study. There are reports indicating that GT or oral
supplements of GTE marketed for weight loss may cause
serious side effects including acute liver toxicity [34]. In
our patients hepatic function remained unchanged during
the observation period.
Orthotopic liver transplantation is currently the only
available causative treatment of familial amyloid poly-
neuropathy and/or cardiomyopathy as it eliminates the
production of the variant amyloid precursor protein [35]
and induces a marked regression (or even disappearance)
of amyloid in abdominal fat [36]. In some patients with
pre-existing cardiac involvement, progression of amyloid
apposition was not halted due to continued deposition of
amyloid aggregates from normal TTR aggregates [37–39].
No therapeutic effect of liver transplantation has been
observed in SSA patients.
Laboratory experiments have shown that EGCG binds to
recombinant wild-type as well as variant TTR tetramers at
three sites different from the thyroxine binding site [15, 40,
41]. A stabilizing effect adding to that of the thyroid hor-
mone was observed. Using a transgenic mice model Ferreira
et al. [17] demonstrated an inhibitory effect of EGCG on
amyloid deposition as well as a degrading effect on pre-
formed amyloid fibrils. The described data, however, were
achieved using a 10–100 fold excess of EGCG over TTR,
far above the observed plasma concentration (0.5 lM) and
applied doses (1 mmol) of EGCG in this trial. However,
using 100 nM fibrillar a-synucleine Bieschke et al. [16]
found significant aggregate-bound EGCG at concentrations
between 20 nM and 1 lM (apparent dissociation constant
0.1 lM). Using isothermal titration calorimetry (ITC)
Ferreira et al. [15] found a dissociation constant of 0.4 lM
for the interaction of non-denaturated TTR and EGCG.
Progression of left ventricular wall mass within a time
span of 1 year was observed in a different group of
untreated patients with mutant ATTR and cardiac
involvement [42]. It is well known that LV mass varies
within the mutation involved and with age at onset of the
disease [43]. Survival of patients with cardiac TTR amy-
loidosis appears to be much better than survival of patients
with light-chain amyloidosis [44, 45]. There is, however, a
wide variation of 5-year survival rates for patients with
different TTR mutations (30–55 %) and among patients
with wild-type TTR amyloidosis (40–75 %) [44–47]. The
patients in Benson’s study group [42] were about 12 years
younger than the patients of our cohort and included
individuals with mutations different from those of our
patients. Therefore, the results of Benson’s and our present
study may not be comparable in a clean scientific approach.
The lack of an appropriate control group will affect final
conclusion from the present observation.
Cardiac MRI is the gold standard for cardiac morphology
and function due to its high reproducibility and low inter-
observer variability [48] and has been used as an endpoint in
several interventional studies, either for reduction of LV
myocardial mass, e. g. arterial hypertension [49], and
Fabry’s disease. Fabry [50] or for quantification of scar size
after TASH procedure in hypertrophic cardiomyopathy
[51]. In the present cohort the reduction of LV myocardial
mass by cMRI was more pronounced than the blinded inter-
observer variability, but appears to be slow, as observed
with enzyme replacement therapy in patients with Fabry’s
disease [52–54]. LV wall mass was found unchanged as
assessed by echocardiography, possibly due to methodo-
logical limitations and limited imaging quality in some
patients. However, improved mitral annulus velocity was
observed as the most accurate diastolic measure to detect
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Fig. 4 MRI changes during the study period left ventricular (LV)
myocardial mass assessed by cardiac MRI in patients with TTR
amyloidosis before (t0) and after 12 months (t12) of green tea
consumption
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early left ventricular dysfunction in patients with AL
amyloidosis [55] and to differentiate restrictive cardiomy-
opathy from pericarditis constrictiva [56]. In comparison
with our echocardiographic data the absolute values of LV
myocardial mass were much lower in the present study
when assessed by cMRI in comparison with echocardiog-
raphy. This reflects a well-known phenomenon [57] that
was recently shown in a report of patients with hereditary
amyloidosis [42, 52]. A possible explanation could be the
inclusion of right ventricular trabecula in the measurement
of the basal septal wall by echocardiography, especially in
patients with massive hypertrophy.
This study was initiated to reproduce Hunstein’s in vivo
observation in ATTR cardiomyopathy patients. A decrease
of about 25 % of left ventricular wall thickness as reported
by Mereles et al. [19] was observed in none of the present
patients. As Hunstein suffered from AL amyloidosis and
had chemotherapy before he started his tea experiment, the
clinical courses of the two different types of disease are not
comparable.
Tafamidis, a novel specific inhibitor of TTR tetramer
dissociation has been evaluated in a prospective placebo-
controlled phase II/III clinical trial in FAP patients and
found to reduce the progression of polyneuropathy in the
majority of patients (http://www.ema.europa.eu/ema/index.
jsp?curl=pages/medicines/human/medicines/002294/human_
med_001498.jsp&mid=WC0b01ac058001d124). The binding
sites of EGCG have been described to be different from those
of known inhibitors for TTR tetramer dissociation [15]. We
conclude that due to different modes of interaction, a combined
treatment with GT/GTE and tafamidis may complement each
other and increase the observed beneficial effects against the
major problems of ATTR amyloidosis patients.
Plasma levels of EGCG 2 h after intake of 150 mg
EGCG ranged from 44 to 840 lg/L. The individual plasma
level of EGCG may be affected by the method of tea
preparation, the instability under physiologic conditions,
differential gastrointestinal absorption, and the modification
by hepatic enzymes [58]. Although we asked our patients to
follow a protocol of GT preparation and to use GTE from a
single manufacturer, significant uncontrollable modifiers of
EGCG bioavailability appear to remain. The endpoint of
our study, i.e. change of LV myocardial mass, may be
affected by components of GT and GTE other than EGCG
bioavailability. We assume that this and a still unknown
variability of the interindividual of EGCG might have
influence on the observed treatment effects. Adjustment of
the individual EGCG plasma levels by appropriate variation
of dose or by supporting an increased intestinal EGCG
uptake by additional consumption of piperine and ascorbic
acid [59] could help ameliorate the effect of treatment. The
daily intake dose of EGCG was restricted by the initial
design of this study, i.e. to reproduce Hunstein’s in vivo
experiment in ATTR cardiomyopathy patients. The lack of
an appropriate control collective taking placebo is due to the
small number of available patients with ATTR cardiomy-
opathy in this country. Furthermore, the rather widespread
knowledge of the results of Hunstein’s experiment among
affected patients resulted in a very low acceptance to
renounce on the use of a possible beneficial effect of GT/
GTE available to everybody. For ATTR cardiomyopathy
being an orphan disease we also were not able to create a
control group from safe retrospective data.
GT has been proven beneficial by consumption for
several thousands of years by many millions of individuals
and is part of the daily routine in the Far East without any
reported side-effects. Therefore, its use may be of interest
for FAC patients and those at age beyond 65 years with no
access to heart transplantation. Randomized, placebo-con-
trolled investigations with longer study periods and larger
samples of patients should confirm the results of this
observation, determine the optimal dosage of GT/GTE for
treatment, and identify undesirable side effects.
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